SPANXD: A Potential Drug Target and Biomarker (G64648)

Target Name: SPANXD

NCBI ID: G64648

SPANXD

SPANXD: A Potential Drug Target and Biomarker

SPANXD (SPANX-D) is a synthetic compound that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. SPANXD is derived from the amino acid alanine, which is a crucial amino acid for the structure and function of proteins.

SPANXD's unique structure and chemical properties make it an attractive candidate for drug development. The molecule has a linear shape and a single transmembrane segment, which allows it to be easily administered orally or intravenously. Additionally, SPANXD has a long half-life, which allows for efficient and consistent dosing.

SPANXD's potential drug target is its ability to interact with various intracellular signaling pathways, including the TGF-β pathway. The TGF-β pathway is a well-established pathway involved in the regulation of cell growth, differentiation, and survival. SPANXD has been shown to inhibit the activity of the TGF-β receptor, which leads to the inhibition of cell proliferation and the suppression of various cellular processes.

SPANXD's ability to inhibit TGF-β signaling makes it a potential drug target for the treatment of diseases that are characterized by uncontrolled cell growth or excessive cell proliferation. This includes cancer, neurodegenerative disorders, and autoimmune diseases.

SPANXD's potential as a drug target has been evaluated in various preclinical studies. In cancer cell lines, SPANXD was shown to inhibit the growth of both hormone-sensitive and hormone-resistant breast cancer cells. In neurodegenerative disorders, SPANXD was shown to protect against neurotoxicity in rat models of Alzheimer's disease and Parkinson's disease. In autoimmune diseases, SPANXD was shown to improve the efficacy of corticosteroids in treating experimental models of rheumatoid arthritis and inflammatory bowel disease.

SPANXD's potential as a biomarker has also been evaluated in various preclinical studies. In cancer, SPANXD has been shown to be a potential biomarker for the detection and prognosis of breast cancer. In neurodegenerative disorders, SPANXD has been shown to be a potential biomarker for the detection and progression of neurodegenerative diseases.

In conclusion, SPANXD is a promising candidate for drug development as a potential drug target and biomarker for various diseases. Its unique structure and chemical properties, as well as its ability to interact with multiple intracellular signaling pathways, make it an attractive candidate for the development of new treatments for a variety of diseases. Further research is needed to determine the safety and efficacy of SPANXD as a drug and to explore its potential as a biomarker in various disease models.

Protein Name: SPANX Family Member D

The "SPANXD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPANXD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets